N/A N=295 A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone
Relapsed and/or Refractory Multiple Myeloma
Primary: Progression-Free Survival (PFS) — 4.79 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=54 A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Biliary Tract Cancer (BTC) · Colorectal Cancer (CRC) · Endometrial Cancer
Primary: Phases 1 and 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) — 8; 6; 13; 7 Participants
N/A N=85 Treatment for Affect Dimensions
Depression · Anxiety
Primary: Positive Affect Subscale of the Positive and Negative Affect Scale (PANAS-P) — 20.76; 29.42; 24.18; 19.42 score on a scale — p=.002
N/A N=60 China (CN)_Magnetic Resonance Imaging (MRI)_Implantable Cardiac Defibrillator (ICD) [CN_MRI_ICD]
Tachycardia
Primary: Number of Participants With Freedom From Magnetic Resonance Imaging (MRI) Scan Related Complications — 14; 14; 15; 12 Participants
N/A N=56 Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
Von Willebrand Diseases
Primary: Total Annualized Bleeding Rate (TABR) — 29.13 Bleeding events per year
N/A N=11 PET Imaging in MCI Following ADT for PCa
Prostate Cancer · Mild Cognitive Impairment
Primary: PET Biomarker Uptake — 0.95; 0.98 Standard Uptake Measure SUV
N/A N=404 Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: Percentage of Participants With Freedom From Primary Safety Events at 12 Months Post-procedure (Acute and Chronic Events) Using the Boston Scientific Cardiac…
N/A N=774 NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"
Relapsed/Refractory Multiple Myeloma
Primary: Number of Participants Reporting One or More Adverse Events (AEs) — 642 Participants
Phase 2 N=46 RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 (Phase 1 and 2) — 8; 38 Participants
Phase 2 N=34 Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Uveal Melanoma
Primary: Relapse Free Survival (RFS) Rate at 32 Months — 50 Probability
N/A N=35 MAP to Health Pilot Study: A Physical Activity Intervention for Midlife Adults
Physical Inactivity
Primary: Meaning Salience — 5.61 score on a scale
Phase 1 N=14 Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Lymphoma · Metastatic Malignant Solid Neoplasm · Metastatic Melanoma
Primary: Maximum Tolerated Dose (MTD))/Recommended Phase 2 Dose of Trigriluzole — 420 mg
N/A N=48 Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)
Renal Cell Carcinoma
Primary: Number of Participants Categorized According to Eastern Cooperative Oncology Group Performance Status (ECOG-PS) — 29; 9; 3; 0 Participants
N/A N=44 Swallowing Impairment After COVID-19 Infection
Covid19
Primary: Number of Participants With Impaired Swallowing Safety — 3; 1 Participants — p=<0.001
Phase 2 N=74 Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Adult Brain Glioblastoma · Glioblastoma Multiforme
Primary: Number of Participants Experiencing Regimen-limiting Toxicity (RLT) — 0; 0 Participants